All In Biotech

Drug Trial Radar · NCT06754098

Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

An Off-Label Single Arm Clinical Study to Evaluate the Efficacy and Safety of Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency.

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Jan 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Cristina Domínguez GonzálezAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
UCB Pharma
First posted
Dec 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the efficacy and safety of Doxecitin and Doxribtimine (dC+dT) in adult participants with thymidine kinase 2 (TK2) deficiency attended in the Neuromuscular Unit of '12 de Octubre' Hospital. The main questions it aims to answer are: * Is dT+dC effective in the treatment of the adult participants with TK2 deficiency? * Is dT+dC safe in the treatment of adult participants with TK2 deficiency? Researchers will evaluate the effectiveness of the treatment doxecitin and doxribthymine in adult participants with TK2 deficiency. In addition, the mitochondrial DNA levels before and after treatment (extracted from the muscle and from uroepithelial cells) of these participants will be also studied.

Conditions

  • Thymidine Kinase 2 (TK2 ) Deficiency
  • Mitochondrial Myopathies

Interventions

  • Doxecitine and DoxribtimineDrug

    A combination of doxecitine and doxribtimine is administered orally in 3 equal doses given approximately 6 to 8 hours apart .Dose will be increased if the tolerability profile is good.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy - Motor Function Assessments: Neurological Exam using Medical Research Council (MRC Scale) Scale for Muscle StrengthTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  2. Efficacy - Motor Function Assessments: 6-minute walk testTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  3. Efficacy - Motor Function Assessments: North Star Ambulatory Assessment (NSAA)Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  4. Efficacy - Motor Function Assessments: 100 meter-time velocity testTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  5. Efficacy - Motor Function Assessments: Fatigue Scale testTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  6. Efficacy - Respiratory Assessments measured by spirometryTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  7. Efficacy - Respiratory Assessments: Use of ventilatory support (Use and Type )Time frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  8. Efficacy - Respiratory Assessments: Time of use of ventilatory supportTime frame: Day 1, Months 1, 2, 3, 12, 15, 18, 21 and 24
  9. Serum Biomarkers: lactate levelsTime frame: Up to 24 months
  10. Serum Biomarkers: Growth/differentiation factor-15 (GDF15 )Time frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.